A double-blind study of the sedative effects of the thalidomide enantiomers in humans

Journal of Pharmacokinetics and Biopharmaceutics

Volumn 26, Issue 4, 1998, Pages 363-383

  Höglund, Peter ^a   Eriksson, Tommy ^a   Björkman, Sven ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Chiral inversion; Concentration effect relationship; Continuous reaction times; Cox regression; Enantiomers; Logistic regression; Sedative effects; Stereospecific analysis; Thalidomide

Indexed keywords

THALIDOMIDE;

ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG MECHANISM; ENANTIOMER; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PRIORITY JOURNAL; REACTION TIME; SEDATION; SYMPTOMATOLOGY;

EID: 2542509655     PISSN: 0090466X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1021008016719     Document Type: Article

References (33)

1. K. Zwingenberger and S. Wnendt. Immunomodulation by thalidomide: Systemic review of the literature and of unpublished observations. J. Inflammation 46:177-211 (1996).
2. R. C. Pogge. Thalidomide: Review of clinical experience with 3140 cases. Appl. Ther. 2:901-908 (1960).
3. H. P. Koch. Thalidomide and congeners as anti-inflammatory agents. Prog. Med. Chem. 22:165-242 (1985).
4. V. Günzler. Thalidomide in human immunodeficiency virus (HIV) patients. Drug Safety 7:116-134 (1992).
5. J. Sheskin. Thalidomide in the treatment of lepra reactions. Clin. Pharmacol. Ther. 6:303-306 (1965).
6. G. B. Vogelsang, E. R. Farmer, A. D. Hess, V. Altamonte, W. E. Beschorner, D. A. Jabs, R. L. Corio, L. S. Levin, O. M. Colvin, J. R. Wingard, and G. W. Santos. Thalidomide for the treatment of chronic graft-versus-host disease. New Engl. J. Med. 326:1055-1058 (1992).
7. S. Ochonisky and J. Revuz. Thalidomide use in dermatology. Eur. J. Dermatol. 4:9-15 (1994).
8. S. Schuler and U. Ehninger. Thalidomide: Rationale for renewed use in immunological disorders. Drug Safety 12:364-369 (1995).
9. C. Marwick. Thalidomide back - under strict control. J. Am. Med. Assoc. 278:1135-1137 (1997).
10. T. Eriksson, S. Björkman, B. Roth, Å. Fyge and P. Höglund. Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide. Chirality 7:44-52 (1995).
11. T. Eriksson and S. Björkman. Handling of blood samples for determination of thalidomide. Clin. Chem. 43:1094-1095 (1997).
12. T. Eriksson, S. Björkman, Å. Fyge, and H. Ekberg. Determination of thalidomide in plasma and blood by high-performance liquid chromatography: Avoiding hydrolytic degradation. J. Chromatog. 582:211-216 (1992).
13. G. Borg, A. Holmgren, and I. Lindblad. Quantitative evaluation of chest pain. Acta Med. Scand. Suppl. 644:43-45 (1981).
14. F. Harder, P. Elsass, J. Hendel, E. F. Hvidberg, and E. Hjørting-Hansen. Clinical and psychological effects of intravenous diazepam related to plasma levels. Int. J. Oral. Surg. 5:226-239 (1976).
15. P. Elsass, J. Hendel, E. F Hvidberg, T. Hansen, E. Gymoese, and J. Rathje. Kinetics and neuropsychologic effects of IV diazepam in the presence and absence of its active N-desmethyl metabolite in humans. Psychopharmacology 70:307-312 (1980).
16. P. Elsass, S.-E. Christensen, L. Ranek, A. Theilgaard, and N. Tygstrup. Continuous reaction time in patients with hepatic encephalopathy. A quantitative measure of changes in consciousness. Scand. J. Gastroent. 16:441-447 (1981).
17. P. Elsass, S.-E. Christensen, E. L. Mortensen, and H. Vilstrup. Discrimination between organic and hepatic encephalopathy by means of continuous reaction times. Liver 5:29-34 (1985).
18. P. Elsass. Continuous reaction times in cerebral dysfunction. Acta Neurol. Scand. 73:225-246 (1986).
19. D. R. Waud. On biological assays involving quantal responses. J. Pharmacol. Exp. Ther. 183:577-607 (1972).
20. J. W. Drane, C. Fu, and T. Postelnicu. Theorems on binary responses to combinations of stimuli. Biometrical Journal 34:605-615 (1992).
21. R. S. Moosa, M. L. McFadyen, R. Miller, and J. Rubin. Carbamazepine and its metabolites in neuralgias: concentration-effect relations. Eur. J. Clin. Pharmacol. 45:297-301 (1993).
22. P. McCullagh and J. A. Nelder. Generalized Linear Models, 2nd ed., Chapman & Hall, London, 1989.
23. J. F. Lawless. Statistical Models and Methods for Lifetime Data, Wiley, New York, 1982.
24. S. Fabro, H. Schumacher, R. L. Smith, R. B. L. Stagg, and R. T. Williams. The metabolism of thalidomide: Some biological effects of thalidomide and its metabolites. Br. J. Pharmacol. 25:352-362 (1965).
25. S. Fabro, R. L. Smith, and R. T. Williams. Toxicity and teratogenicity of optical isomers of thalidomide. Nature 215:296 (1967).
26. H. P. Büch, G. Omlor, and J. Knabe. Stereoselektive Unterschiede der zentralnervös depressorischen Wirkung in einer homologen Reihe von 3-Alkyl-Thalidomide-Analogs. Arzneim. Forsch. 40:32-36 (1990).
27. D. Westerling, L. Frigren, and P. Höglund. Morphine pharmacokinetics and effects on salivation and continuous reaction times in healthy volunteers. Ther. Drug Monit. 15:364-374 (1993).
28. P. Sjøgren and A. Banning. Pain, sedation and reaction time during long-term treatment of cancer patients with oral and epidural opioids. Pain 39:5-11 (1989).
29. J. N. Green and B. N. Benson. The spectrophotometric determination of thalidomide in body fluids. J. Pharm. Pharmacol. 13:117T-121T (1961).
30. R. Beckman and H. H. Kampf. Zur quantitativen Bestimmung und zum qualitativen Nachweis von N-Phthalyl-Glutaminsäure-Imid (Thalidomide). Arzneim. Forsch. 11:185-190 (1961).
31. T.-L. Chen, G. B. Vogelsang, B. G. Petty, R. B. Brundrett, D. A. Noe, G. W. Santos, and O. M. Colvin. Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. Drug. Metab. Dispos. 17:402-405 (1989).
32. G. Reyés-Teran, J. G. Sierra-Madero, V. M. del Cerro, H. Arroyo-Figueroa, A. Pasquetti, J. J. Calva, and G. M. Ruiz-Palacios. Effects of thalidomide on HIV-associated wasting syndrome: A randomized, double-blind, placebo-controlled clinical trial. AIDS 10:1501-1507 (1996).
33. S. Wnendt, M. Finkam, W. Winter, J. Ossig, G. Raabe, and K. Zwingenberger. Enantio-selective inhibition of TNF-α release by thalidomide and thalidomide analogues. Chirality 8:390-396 (1996).